These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15087061)

  • 21. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.
    Chun KH; Lee HY; Hassan K; Khuri F; Hong WK; Lotan R
    Cancer Res; 2003 Aug; 63(16):4796-800. PubMed ID: 12941797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro.
    Izbicka E; Campos D; Carrizales G; Patnaik A
    Anticancer Res; 2005; 25(5):3215-23. PubMed ID: 16101130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
    Cohen SJ; Ho L; Ranganathan S; Abbruzzese JL; Alpaugh RK; Beard M; Lewis NL; McLaughlin S; Rogatko A; Perez-Ruixo JJ; Thistle AM; Verhaeghe T; Wang H; Weiner LM; Wright JJ; Hudes GR; Meropol NJ
    J Clin Oncol; 2003 Apr; 21(7):1301-6. PubMed ID: 12663718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The American Society of Hematology--46th Annual Meeting and Exposition. HDAC, Flt and farnesyl transferase inhibitors.
    Evans L
    IDrugs; 2005 Jan; 8(1):4-6. PubMed ID: 15650931
    [No Abstract]   [Full Text] [Related]  

  • 25. Influence of farnesyl transferase inhibitor treatment on epidermal growth factor receptor status.
    Cornelissen B; Thonissen T; Kersemans V; Van De Wiele C; Lahorte C; Dierckx RA; Slegers G
    Nucl Med Biol; 2004 Aug; 31(6):679-89. PubMed ID: 15246358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Farnesyl transferase inhibitors for patients with lung cancer.
    Johnson BE; Heymach JV
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4254s-4257s. PubMed ID: 15217969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.
    Heymach JV; Johnson DH; Khuri FR; Safran H; Schlabach LL; Yunus F; DeVore RF; De Porre PM; Richards HM; Jia X; Zhang S; Johnson BE
    Ann Oncol; 2004 Aug; 15(8):1187-93. PubMed ID: 15277257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.
    Rao S; Cunningham D; de Gramont A; Scheithauer W; Smakal M; Humblet Y; Kourteva G; Iveson T; Andre T; Dostalova J; Illes A; Belly R; Perez-Ruixo JJ; Park YC; Palmer PA
    J Clin Oncol; 2004 Oct; 22(19):3950-7. PubMed ID: 15459217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
    Kurzrock R; Cortes J; Kantarjian H
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):20-4. PubMed ID: 12447848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
    End DW; Smets G; Todd AV; Applegate TL; Fuery CJ; Angibaud P; Venet M; Sanz G; Poignet H; Skrzat S; Devine A; Wouters W; Bowden C
    Cancer Res; 2001 Jan; 61(1):131-7. PubMed ID: 11196150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
    Smalley KS; Eisen TG
    Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
    Kurzrock R; Kantarjian HM; Blascovich MA; Bucher C; Verstovsek S; Wright JJ; Pilat SR; Cortes JE; Estey EH; Giles FJ; Beran M; Sebti SM
    Clin Cancer Res; 2008 Jan; 14(2):509-14. PubMed ID: 18223226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Cortes J
    Clin Lymphoma; 2003 Aug; 4 Suppl 1():S30-5. PubMed ID: 14556673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis.
    Andela VB; Rosenblatt JD; Schwarz EM; Puzas EJ; O'Keefe RJ; Rosier RN
    Clin Orthop Relat Res; 2002 Apr; (397):228-39. PubMed ID: 11953614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery.
    Venet M; End D; Angibaud P
    Curr Top Med Chem; 2003; 3(10):1095-102. PubMed ID: 12769710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors.
    Du W; Liu A; Prendergast GC
    Cancer Res; 1999 Sep; 59(17):4208-12. PubMed ID: 10485456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
    Pei XY; Dai Y; Rahmani M; Li W; Dent P; Grant S
    Clin Cancer Res; 2005 Jun; 11(12):4589-600. PubMed ID: 15958645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
    Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.